Sponsored
Matt Whelihan, associate director of research and development at Prolytix, discusses industry trends—from data-driven approaches built on artificial intelligence (AI) to increasingly complex therapeutic modalities.
Matthew Whelihan, PhD, Associate Director of Research and Development
Advertisement
Articles by Matthew Whelihan, PhD, Associate Director of Research and Development
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
3
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
4
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
5